Shots:
- The US FDA has approved Avtozma IV, a biosimilar to Actemra (tocilizumab), for treating cytokine release syndrome in pts (≥2yrs.), covering all Actemra IV-approved indications in the US; expected to be available in the US by Aug 31, 2025
- In Jan 2025, the US FDA approved Avtozma IV to treat rheumatoid arthritis (RA), giant cell arteritis (GCA), polyarticular juvenile idiopathic arthritis (pJIA), systemic juvenile idiopathic arthritis (sJIA) & COVID-19
- Additionally, Celltrion holds the commercialization rights of the Avtozma SC formulation in the US, with the licensed launch date remaining confidential
Ref: Celltrion| Image: Celltrion| Press Release
Related News:- Celltrion Launches Osenvelt and Stoboclo (Biosimilars, Xgeva and Prolia) in the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
